Management of the stage IIIA (N2) patient remains one of the most controversial areas in thoracic oncology. The potential cur-ability of at least some of these patients has encourage the development of more complex, aggressive, and toxic multimodality treatment regimens.
|Original language||English (US)|
|Number of pages||32|
|Journal||Chest Surgery Clinics of North America|
|State||Published - Mar 26 2001|
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine